Finance 20 May 2026 - 21 May 2026

ChampionsGate Stock Little Changed as SPAC Deal Timeline Gets Attention
····

ChampionsGate Stock Little Changed as SPAC Deal Timeline Gets Attention

ChampionsGate Acquisition Corporation stock was flat in premarket trading Wednesday. The Nasdaq-listed SPAC stayed near the level investors could redeem for cash if the company doesn’t seal a merger. The stock last changed hands at $10.35, off 0.07% in the past 24 hours. TradingView data showed the market shut with no fresh trades on the tape at the time. It had a market cap near $103.4 million.
June 3, 2026
First Advantage Stock Pops Again — But Investors Are Still Testing the Earnings Story
····

First Advantage Stock Pops Again — But Investors Are Still Testing the Earnings Story

First Advantage Corp shares head into Thursday’s pre-market session with fresh momentum after gaining 2.55% to $15.28 on Wednesday, as investors kept working through the background-screening company’s stronger first-quarter results and a more mixed outside view on valuation. The move matters now because the stock has been climbing with the broader market but is still being judged against a big question: whether First Advantage can turn post-Sterling scale, cost savings and digital-identity demand into steadier profit growth. Nasdaq lists regular trading from 9:30 a.m. to 4 p.m. Eastern time, with pre-market trade starting at 4 a.m.; the next U.S. market holiday is Memorial Day on May 25.
May 21, 2026
Braze Shares Move Ahead of Results as Traders Watch AI Drive and CFO Departure
····

Braze Shares Move Ahead of Results as Traders Watch AI Drive and CFO Departure

Braze Inc shares gained roughly 5% in recent U.S. trading, with the customer-engagement software stock showing up ahead of its earnings next week and a coming CFO change. BRZE last traded at $22.82, up $1.07 from the last close. Nasdaq trading was still in pre-market hours at the time. Pre-market runs 4:00 a.m. to 9:30 a.m. ET, while regular trading goes from 9:30 a.m. to 4:00 p.m. The exchange's 2026 calendar puts the next U.S. market holiday on Memorial Day, May 25.
May 21, 2026
AMOD Stock Alert: Alpha Modus’ Android Launch Puts This Tiny Fintech Bet on the Clock
····

AMOD Stock Alert: Alpha Modus’ Android Launch Puts This Tiny Fintech Bet on the Clock

Alpha Modus Holdings Inc.’s AMOD shares hovered near 20 cents early Thursday after the company said its Alpha Cash financial app had gone live on Android, a small product milestone for a Nasdaq-listed stock still under heavy pressure. The shares closed Wednesday at $0.20, down 5.09%, and were quoted at $0.21 in extended trading as of 4:29 a.m. Eastern. The timing matters because Alpha Modus is trying to turn a string of fintech announcements into measurable distribution and revenue. The company said Wednesday that Google Play availability completed the app’s rollout across both iOS and Android, one day before a regular U.S. trading session; Nasdaq’s 2026 holiday calendar lists the next full closure as Memorial Day on May 25.
May 21, 2026
Kingsoft Cloud Stock Drops Again in Run-Up to Earnings
····

Kingsoft Cloud Stock Drops Again in Run-Up to Earnings

Kingsoft Cloud Holdings' U.S.-traded ADRs headed lower in early indications ahead of the New York open Thursday, after slipping 4.3% in the previous session. Investors are weighing whether the China cloud company's AI narrative will carry over into next week’s earnings report. Shares finished at $13.96 on Wednesday and changed hands at $13.45 early Thursday, based on StockAnalysis. Market cap was around $4.19 billion.
May 21, 2026
Jaguar Health Shares Spike After 816% Revenue Jump, But Trial Results Still Key
····

Jaguar Health Shares Spike After 816% Revenue Jump, But Trial Results Still Key

Jaguar Health Inc. shares rose Wednesday as the small drugmaker posted an 816% surge in first-quarter revenue. The bump came after a licensing deal that transferred U.S. commercial rights for Mytesi and Canalevia-CA1 to Woodward Specialty, which is linked to privately held Future Pak. Shares finished the day at $3.67, gaining 9.2% from $3.36 on Tuesday. Trading volume jumped to 593,152 shares from 69,266, Jaguar’s LSEG-based price table showed.
May 21, 2026
Star Bulk Stock Gets a Dividend Jolt as SBLK Cash Returns Take Center Stage
····

Star Bulk Stock Gets a Dividend Jolt as SBLK Cash Returns Take Center Stage

Star Bulk Carriers Corp. shares held near Wednesday’s gain in early U.S. pre-market trade after the dry-bulk shipper reported a sharp first-quarter profit rebound and a higher quarterly dividend. The Nasdaq-listed stock closed at $26.69, up 2.34%, and was quoted at $26.70 before regular trading opened. The move matters now because the earnings put hard numbers behind Star Bulk’s full-payout dividend policy, a draw for investors in a shipping segment where cash flow can swing with freight rates. Dry bulk means unpackaged cargo such as iron ore, grain and minerals; Star Bulk uses time-charter equivalent, or TCE, as a measure of average daily net revenue after voyage costs.
May 21, 2026
Akebia Shares Bounce 12% After Volatile Session
····

Akebia Shares Bounce 12% After Volatile Session

Akebia Therapeutics shares rallied in late U.S. trading Wednesday, clawing back after falling for two straight sessions. Investors moved into select smaller biotech stocks. Akebia was last at $1.01, up roughly 12%. Shares earlier dipped to an intraday low of 89.32 cents. AKBA’s trading looks less like a reaction to earnings and more like a bet on Vafseo, its new anemia drug. Shares finished Monday at $1.01, then slipped to 90 cents on Tuesday, according to LSEG data on the company’s investor page.
May 21, 2026
BioVie Stock Pops After Parkinson’s Trial Milestone. The Real Test Comes in Q3
····

BioVie Stock Pops After Parkinson’s Trial Milestone. The Real Test Comes in Q3

BioVie Inc. shares rose on Wednesday after the clinical-stage drug developer said its SUNRISE-PD Parkinson’s trial had completed the last patient evaluation visit, moving the story from enrollment and dosing toward data. The stock closed at $1.35, up 3.05%, after trading between $1.31 and $1.37. That matters now because BioVie is a small, low-volume biotech whose valuation is tied closely to clinical events. At Wednesday’s close, the company had a market value of about $10.2 million, and trading volume was 19,735 shares, below the 89,680 average shown by Google Finance.
May 21, 2026
NAII Stock Gains Despite Wider Loss, Cash Still the Focus
····

NAII Stock Gains Despite Wider Loss, Cash Still the Focus

Natural Alternatives International Inc. stock gained Wednesday, though the nutritional supplements maker posted a larger fiscal third-quarter loss. Investors looked past the loss, focusing on higher sales, slimmer margins, and news of new refinancing. NAII shares last changed hands at $2.59, about 1.8% higher, with 10,040 shares traded. The company has a market cap close to $15.6 million. NAII is still in micro-cap territory, which means it carries a small market value and usually sees thin trading.
May 21, 2026
HeartCore Cash Concerns Leave HTCR Shares Flat
····

HeartCore Cash Concerns Leave HTCR Shares Flat

HeartCore Enterprises Inc. was last seen at $2.70 in after-hours trading Wednesday, up 2 cents. The microcap hovered near its lows, holding a market cap of about $3.4 million. Most recent trade was at 4:45 p.m. EDT. Trading volume was light. Just 23,040 shares changed hands, far below the typical 52,270 average. With less activity, smaller trades had a bigger impact on price.
May 20, 2026
CG Oncology Shares Gain Ahead of Bladder Cancer Update; Wolfe Urges Caution
···

CG Oncology Shares Gain Ahead of Bladder Cancer Update; Wolfe Urges Caution

CG Oncology shares edged higher Wednesday as traders looked for direction and watched for the next update on its bladder-cancer drug, cretostimogene grenadenorepvec. The stock was recently quoted at $64.76, up 2.3%. Volume was near 768,000 shares. CG Oncology isn’t just a small biotech with a long runway anymore. The stock now trades around a near-term trial readout, a planned regulatory filing, and early Wall Street arguments over how quickly the drug could move if it wins approval. The company said it plans a biologics license application, or BLA, which is the main U.S. route for getting a biologic medicine cleared.
May 20, 2026
Esperion Shares Flat at $3.16 as Archimed Bid Nears Endgame
····

Esperion Shares Flat at $3.16 as Archimed Bid Nears Endgame

Esperion Therapeutics shares stayed flat at $3.13 late Wednesday, just under Archimed’s $3.16-a-share cash offer. Investors are looking at what’s left in the take-private deal and the open milestone risks. The stock moved in a tight range from $3.13 to $3.14, with volume topping 7 million shares. Esperion isn’t just a small-cap drug name trading on growth anymore. Now it’s more of a merger spread play, with shares moving on the gap between the deal price and where it trades. The spread’s slim, but still there.
May 20, 2026
Why Revelation Biosciences Stock Jumped Today as Traders Eye Its Kidney-Drug Bet
····

Why Revelation Biosciences Stock Jumped Today as Traders Eye Its Kidney-Drug Bet

Revelation Biosciences shares were quoted at $1.09 after the U.S. market close on Wednesday, up $0.06, or 5.82%, giving the clinical-stage biotech a market value of about $4.1 million. The move beat a firmer Nasdaq session, with the broader index up about 1.55% late in the day. The gain was not a catch-up trade after a holiday. Nasdaq’s 2026 calendar lists Memorial Day on May 25 as the next U.S. market closure, leaving Wednesday as a regular trading session for REVB.
May 20, 2026
Ituran Shares Tick Higher Ahead of Results
····

Ituran Shares Tick Higher Ahead of Results

Ituran Location and Control Ltd. shares edged up 0.39% to $57.17 Wednesday on Nasdaq. Investors are waiting for the vehicle-telematics company’s first-quarter report next week. Around 77,164 shares changed hands. The company has a market cap near $1.14 billion. Shares finished below their 52-week high of $62.31. Ituran’s move is getting attention with its earnings report set for six days from now. The company is due to post Q1 2026 results on May 26 and will hold a management call for investors at 9 a.m. Eastern. Management will discuss results and take questions.
May 20, 2026
Fifth Era Stock Little Changed as Traders Watch $10 Billion Metals Deal
····

Fifth Era Stock Little Changed as Traders Watch $10 Billion Metals Deal

Fifth Era Acquisition Corp I was flat in quiet Nasdaq trade Wednesday, with shares near the cash amount investors could get if its merger deal with strategic metals firm Miotal falls apart. That’s what’s happening with the stock lately. FERA isn’t trading like a regular operating company. It’s moving more like a SPAC, or special purpose acquisition company. In other words, a shell from an IPO out to merge with a private firm.
May 20, 2026
CoinShares Shares Recover After $1 Billion Fund Exit Hits Nasdaq Debutant
····

CoinShares Shares Recover After $1 Billion Fund Exit Hits Nasdaq Debutant

CoinShares PLC shares bounced back Wednesday, recovering some ground after a steep drop. Investors looked at another round of outflows from crypto funds and the firm’s move to attract U.S. institutions following its Nasdaq debut. The stock rose 3.3% to $5.33 on the Nasdaq in afternoon trading. Session range was $5.17 to $5.405. About 172,000 shares changed hands by late afternoon, below volumes in bigger crypto-linked stocks. Bitcoin traded close to $77,354, with ether near $2,130.
May 20, 2026
Immutep Shares Drop as Investors Face Trial Setback, Lawsuit Date and Nasdaq Alert
····

Immutep Shares Drop as Investors Face Trial Setback, Lawsuit Date and Nasdaq Alert

Immutep Ltd’s Nasdaq ADRs dropped around 5% Wednesday afternoon, missing out on gains in the biotech sector. New investor-law firm notices added to investor focus on lawsuits over the failed lung-cancer trial. The ADRs last changed hands at $0.4778, off a low of $0.4606. The SPDR S&P Biotech ETF climbed about 3.5%. Immutep is under pressure as it deals with a stock price below $1 on Nasdaq, shareholder litigation notices and efforts to recover trust following the halt of its TACTI-004 Phase III trial in first-line non-small cell lung cancer in March. Nasdaq’s regular U.S. market hours are 9:30 a.m. to 4 p.m. Eastern, according to Nasdaq.
May 20, 2026
1 … 32 33 34 35 36 … 220